| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Transfusion | 41 | 2023 | 1301 | 5.050 |
Why?
|
| Erythrocyte Transfusion | 15 | 2020 | 565 | 2.360 |
Why?
|
| Acidosis, Lactic | 6 | 2018 | 142 | 2.200 |
Why?
|
| Blood Preservation | 15 | 2016 | 177 | 1.830 |
Why?
|
| Plasma | 14 | 2018 | 575 | 1.720 |
Why?
|
| Malaria, Falciparum | 9 | 2018 | 1077 | 1.670 |
Why?
|
| Anemia | 11 | 2019 | 1503 | 1.660 |
Why?
|
| Plasma Exchange | 6 | 2020 | 152 | 1.610 |
Why?
|
| ABO Blood-Group System | 8 | 2012 | 367 | 1.430 |
Why?
|
| Blood Component Transfusion | 11 | 2019 | 143 | 1.330 |
Why?
|
| Blood Platelets | 17 | 2021 | 2509 | 1.150 |
Why?
|
| Hemorrhage | 11 | 2020 | 3461 | 1.090 |
Why?
|
| Plasmodium falciparum | 8 | 2013 | 1732 | 1.070 |
Why?
|
| Thrombocytopenia | 7 | 2021 | 1178 | 1.030 |
Why?
|
| Erythrocytes | 17 | 2023 | 2455 | 0.980 |
Why?
|
| Leukocyte Count | 15 | 2003 | 1588 | 0.890 |
Why?
|
| Blood Specimen Collection | 5 | 2018 | 246 | 0.830 |
Why?
|
| Blood Donors | 10 | 2013 | 355 | 0.750 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2020 | 652 | 0.730 |
Why?
|
| Oxygen Consumption | 3 | 2016 | 1868 | 0.700 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2021 | 183 | 0.680 |
Why?
|
| Drugs, Investigational | 2 | 2015 | 214 | 0.670 |
Why?
|
| Uganda | 10 | 2019 | 1237 | 0.670 |
Why?
|
| Liver Transplantation | 15 | 2023 | 2119 | 0.660 |
Why?
|
| Blood Transfusion, Autologous | 9 | 2012 | 134 | 0.660 |
Why?
|
| von Willebrand Factor | 2 | 2019 | 669 | 0.640 |
Why?
|
| Leukocytes | 10 | 2002 | 2045 | 0.620 |
Why?
|
| Blood Banks | 6 | 2018 | 111 | 0.610 |
Why?
|
| Platelet Transfusion | 6 | 2014 | 314 | 0.600 |
Why?
|
| Hypertriglyceridemia | 1 | 2020 | 293 | 0.600 |
Why?
|
| von Willebrand Diseases | 1 | 2019 | 127 | 0.590 |
Why?
|
| Blood Component Removal | 6 | 2005 | 125 | 0.570 |
Why?
|
| Heparin | 3 | 2020 | 1637 | 0.570 |
Why?
|
| DNA, Mitochondrial | 2 | 2018 | 817 | 0.560 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2020 | 260 | 0.560 |
Why?
|
| Blood Grouping and Crossmatching | 5 | 2009 | 108 | 0.560 |
Why?
|
| Tranexamic Acid | 1 | 2017 | 146 | 0.540 |
Why?
|
| Hemostasis | 4 | 2023 | 458 | 0.520 |
Why?
|
| Oxygen | 4 | 2016 | 4189 | 0.500 |
Why?
|
| Cell Separation | 10 | 2002 | 1751 | 0.490 |
Why?
|
| Monocytes | 4 | 2012 | 2596 | 0.490 |
Why?
|
| Safety | 4 | 2005 | 1186 | 0.490 |
Why?
|
| Blood Coagulation | 3 | 2020 | 1127 | 0.480 |
Why?
|
| Abdominal Neoplasms | 1 | 2015 | 292 | 0.470 |
Why?
|
| Pancreatitis | 1 | 2020 | 1092 | 0.460 |
Why?
|
| Malaria | 3 | 2013 | 1239 | 0.460 |
Why?
|
| Factor VIII | 4 | 2019 | 347 | 0.450 |
Why?
|
| Blood Coagulation Factors | 1 | 2015 | 355 | 0.440 |
Why?
|
| Platelet Count | 8 | 2021 | 780 | 0.440 |
Why?
|
| Host-Parasite Interactions | 2 | 2011 | 295 | 0.430 |
Why?
|
| Hemostatics | 1 | 2015 | 229 | 0.430 |
Why?
|
| Specimen Handling | 2 | 2015 | 694 | 0.420 |
Why?
|
| ADAM Proteins | 2 | 2015 | 243 | 0.410 |
Why?
|
| Cytochromes b | 1 | 2011 | 36 | 0.410 |
Why?
|
| Flow Cytometry | 9 | 2012 | 5974 | 0.410 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2020 | 980 | 0.410 |
Why?
|
| Blood Coagulation Tests | 5 | 2011 | 263 | 0.400 |
Why?
|
| Patient Identification Systems | 6 | 2009 | 79 | 0.390 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2012 | 1159 | 0.390 |
Why?
|
| Leukapheresis | 3 | 2000 | 131 | 0.390 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 1856 | 0.390 |
Why?
|
| Humans | 174 | 2024 | 744366 | 0.380 |
Why?
|
| Air | 1 | 2011 | 182 | 0.370 |
Why?
|
| Medical Errors | 7 | 2020 | 1297 | 0.360 |
Why?
|
| Rh-Hr Blood-Group System | 2 | 2009 | 65 | 0.360 |
Why?
|
| Heart Arrest | 1 | 2020 | 1470 | 0.350 |
Why?
|
| Hemophilia A | 2 | 2013 | 351 | 0.350 |
Why?
|
| Blood Safety | 2 | 2019 | 14 | 0.340 |
Why?
|
| Prothrombin Time | 2 | 2006 | 119 | 0.340 |
Why?
|
| Operating Rooms | 4 | 2020 | 817 | 0.330 |
Why?
|
| Blood Group Antigens | 4 | 2000 | 180 | 0.310 |
Why?
|
| Child, Preschool | 16 | 2020 | 41005 | 0.310 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2016 | 1572 | 0.300 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 4 | 2020 | 131 | 0.290 |
Why?
|
| Nitric Oxide | 3 | 2016 | 2132 | 0.290 |
Why?
|
| Plasmapheresis | 2 | 2007 | 211 | 0.290 |
Why?
|
| Boronic Acids | 1 | 2011 | 965 | 0.290 |
Why?
|
| Quinidine | 1 | 2006 | 57 | 0.290 |
Why?
|
| Carbon Dioxide | 1 | 2011 | 1150 | 0.280 |
Why?
|
| Infant | 16 | 2019 | 35134 | 0.280 |
Why?
|
| Hemoglobin A | 2 | 2016 | 87 | 0.280 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2007 | 277 | 0.270 |
Why?
|
| Hospitals, General | 3 | 2014 | 749 | 0.270 |
Why?
|
| Insulin | 1 | 2020 | 6582 | 0.270 |
Why?
|
| Filtration | 7 | 2002 | 234 | 0.270 |
Why?
|
| HLA Antigens | 5 | 2014 | 1382 | 0.260 |
Why?
|
| Mitochondrial Proteins | 1 | 2011 | 994 | 0.260 |
Why?
|
| Pyrazines | 1 | 2011 | 1230 | 0.260 |
Why?
|
| Wounds and Injuries | 2 | 2023 | 2400 | 0.260 |
Why?
|
| Blood Coagulation Disorders | 3 | 2006 | 337 | 0.260 |
Why?
|
| Factor VIIa | 1 | 2006 | 101 | 0.260 |
Why?
|
| Foundations | 1 | 2005 | 94 | 0.260 |
Why?
|
| Severity of Illness Index | 9 | 2020 | 15535 | 0.250 |
Why?
|
| Thrombotic Microangiopathies | 2 | 2017 | 132 | 0.250 |
Why?
|
| Patient Care | 1 | 2010 | 640 | 0.250 |
Why?
|
| Plateletpheresis | 3 | 1997 | 47 | 0.250 |
Why?
|
| Isoantibodies | 3 | 2014 | 679 | 0.240 |
Why?
|
| Purpura Fulminans | 1 | 2024 | 22 | 0.240 |
Why?
|
| Drug Labeling | 1 | 2006 | 233 | 0.230 |
Why?
|
| Platelet Aggregation | 3 | 2005 | 798 | 0.230 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2023 | 125 | 0.220 |
Why?
|
| Medical Audit | 1 | 2004 | 467 | 0.220 |
Why?
|
| Hematologic Neoplasms | 1 | 2015 | 1832 | 0.220 |
Why?
|
| Resuscitation | 3 | 2023 | 658 | 0.220 |
Why?
|
| Evolution, Molecular | 1 | 2011 | 1939 | 0.220 |
Why?
|
| Male | 54 | 2021 | 350115 | 0.210 |
Why?
|
| Female | 52 | 2021 | 380193 | 0.200 |
Why?
|
| Medical Waste | 2 | 2018 | 14 | 0.200 |
Why?
|
| Hemoglobins | 5 | 2016 | 1532 | 0.200 |
Why?
|
| Acute Kidney Injury | 2 | 2011 | 1968 | 0.190 |
Why?
|
| Renal Insufficiency | 1 | 2007 | 804 | 0.190 |
Why?
|
| Research Support as Topic | 1 | 2005 | 705 | 0.190 |
Why?
|
| Lactic Acid | 2 | 2018 | 1132 | 0.190 |
Why?
|
| Lymphocyte Culture Test, Mixed | 2 | 1993 | 518 | 0.190 |
Why?
|
| Malaria, Cerebral | 2 | 2013 | 135 | 0.180 |
Why?
|
| Antimalarials | 1 | 2006 | 905 | 0.170 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2021 | 142 | 0.170 |
Why?
|
| Gamma Rays | 4 | 2000 | 320 | 0.170 |
Why?
|
| Parasitemia | 2 | 2013 | 173 | 0.170 |
Why?
|
| Hematologic Diseases | 1 | 2023 | 498 | 0.170 |
Why?
|
| Brain | 2 | 2016 | 26388 | 0.170 |
Why?
|
| Pathology, Clinical | 2 | 2014 | 368 | 0.170 |
Why?
|
| Isoantigens | 3 | 2000 | 567 | 0.170 |
Why?
|
| Fibrinogen | 3 | 2019 | 894 | 0.160 |
Why?
|
| Multiple Organ Failure | 1 | 2021 | 389 | 0.160 |
Why?
|
| Transforming Growth Factor beta | 2 | 2003 | 2007 | 0.160 |
Why?
|
| Renal Replacement Therapy | 1 | 2020 | 257 | 0.160 |
Why?
|
| Intraoperative Complications | 2 | 2004 | 1198 | 0.160 |
Why?
|
| Liver | 5 | 2023 | 7475 | 0.160 |
Why?
|
| Africa South of the Sahara | 3 | 2019 | 724 | 0.160 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2002 | 233 | 0.160 |
Why?
|
| Genotype | 1 | 2012 | 12952 | 0.160 |
Why?
|
| Thrombosis | 2 | 2023 | 2968 | 0.160 |
Why?
|
| Blood | 2 | 1995 | 598 | 0.150 |
Why?
|
| Hospital Distribution Systems | 1 | 2017 | 5 | 0.150 |
Why?
|
| Critical Care | 4 | 2020 | 2647 | 0.150 |
Why?
|
| Antigens, CD34 | 1 | 1999 | 659 | 0.150 |
Why?
|
| Time Factors | 10 | 2016 | 40075 | 0.150 |
Why?
|
| Health Care Costs | 2 | 2010 | 3208 | 0.150 |
Why?
|
| Caregivers | 2 | 2019 | 2095 | 0.150 |
Why?
|
| Coronary Artery Bypass | 2 | 2004 | 2288 | 0.150 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2008 | 2214 | 0.140 |
Why?
|
| Biological Products | 1 | 2006 | 860 | 0.140 |
Why?
|
| Endothelium, Vascular | 2 | 2009 | 4459 | 0.140 |
Why?
|
| Oxidative Phosphorylation | 1 | 2018 | 481 | 0.140 |
Why?
|
| Hospitalization | 2 | 2020 | 10259 | 0.140 |
Why?
|
| Hemostatic Techniques | 1 | 2017 | 116 | 0.140 |
Why?
|
| Gene Expression Regulation | 2 | 2012 | 12073 | 0.140 |
Why?
|
| Creatinine | 2 | 2016 | 1919 | 0.140 |
Why?
|
| Vasodilator Agents | 1 | 2020 | 976 | 0.140 |
Why?
|
| Hypotension | 1 | 2002 | 884 | 0.140 |
Why?
|
| Fever | 3 | 2006 | 1616 | 0.140 |
Why?
|
| Hemolysis | 5 | 2021 | 420 | 0.130 |
Why?
|
| National Health Programs | 1 | 2019 | 445 | 0.130 |
Why?
|
| Diagnosis, Differential | 5 | 2020 | 12961 | 0.130 |
Why?
|
| Adult | 34 | 2023 | 214052 | 0.130 |
Why?
|
| Biological Availability | 1 | 2016 | 397 | 0.130 |
Why?
|
| Treatment Outcome | 8 | 2020 | 63107 | 0.130 |
Why?
|
| Lactates | 1 | 2015 | 432 | 0.130 |
Why?
|
| Middle Aged | 31 | 2020 | 213390 | 0.120 |
Why?
|
| Length of Stay | 5 | 2020 | 6311 | 0.120 |
Why?
|
| Physicians | 2 | 2010 | 4567 | 0.120 |
Why?
|
| Case-Control Studies | 3 | 2021 | 21748 | 0.120 |
Why?
|
| IgA Deficiency | 1 | 2013 | 43 | 0.110 |
Why?
|
| Liver Neoplasms | 2 | 2008 | 4253 | 0.110 |
Why?
|
| 2,3-Diphosphoglycerate | 2 | 2011 | 15 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 3873 | 0.110 |
Why?
|
| Drug Storage | 1 | 2013 | 51 | 0.110 |
Why?
|
| Multiple Myeloma | 2 | 2011 | 5181 | 0.110 |
Why?
|
| Quality Control | 4 | 2000 | 841 | 0.110 |
Why?
|
| Biological Evolution | 2 | 2011 | 1077 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 3 | 1997 | 6171 | 0.110 |
Why?
|
| Postoperative Complications | 8 | 2008 | 15297 | 0.110 |
Why?
|
| Lymphocytes | 3 | 1993 | 2617 | 0.110 |
Why?
|
| Electronic Health Records | 2 | 2020 | 4468 | 0.110 |
Why?
|
| Triglycerides | 1 | 2020 | 2453 | 0.110 |
Why?
|
| Hospitals | 2 | 2003 | 3954 | 0.110 |
Why?
|
| Polyneuropathies | 1 | 2014 | 137 | 0.110 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2010 | 1261 | 0.110 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2014 | 151 | 0.110 |
Why?
|
| Formaldehyde | 2 | 1996 | 353 | 0.110 |
Why?
|
| Disease Management | 2 | 2021 | 2460 | 0.110 |
Why?
|
| Splenomegaly | 1 | 2013 | 190 | 0.110 |
Why?
|
| Transplantation Immunology | 1 | 1994 | 546 | 0.110 |
Why?
|
| Transplantation Chimera | 1 | 1995 | 613 | 0.110 |
Why?
|
| Gorilla gorilla | 1 | 2011 | 30 | 0.100 |
Why?
|
| Boston | 4 | 2006 | 9312 | 0.100 |
Why?
|
| Exsanguination | 1 | 2011 | 27 | 0.100 |
Why?
|
| Hemofiltration | 1 | 1992 | 57 | 0.100 |
Why?
|
| Child | 11 | 2019 | 77709 | 0.100 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 1992 | 141 | 0.100 |
Why?
|
| Leukocytosis | 1 | 2013 | 247 | 0.100 |
Why?
|
| Blood Loss, Surgical | 3 | 2013 | 662 | 0.100 |
Why?
|
| Ultrafiltration | 2 | 1996 | 57 | 0.100 |
Why?
|
| Immunogenetic Phenomena | 1 | 2011 | 23 | 0.100 |
Why?
|
| Infant, Premature | 1 | 2020 | 2045 | 0.100 |
Why?
|
| Cesarean Section | 1 | 2020 | 1365 | 0.100 |
Why?
|
| Sepsis | 2 | 2024 | 2593 | 0.100 |
Why?
|
| Hyperemia | 1 | 2012 | 225 | 0.100 |
Why?
|
| Clinical Trials as Topic | 2 | 2006 | 7914 | 0.100 |
Why?
|
| Centrifugation | 1 | 1991 | 122 | 0.100 |
Why?
|
| Pregnancy | 4 | 2021 | 29144 | 0.090 |
Why?
|
| Immunologic Factors | 1 | 2020 | 1580 | 0.090 |
Why?
|
| Fibrinolysis | 2 | 1990 | 322 | 0.090 |
Why?
|
| Postoperative Hemorrhage | 1 | 2014 | 412 | 0.090 |
Why?
|
| Drug Approval | 3 | 2006 | 742 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 6489 | 0.090 |
Why?
|
| Retrospective Studies | 12 | 2023 | 77460 | 0.090 |
Why?
|
| Nerve Fibers | 1 | 2014 | 687 | 0.090 |
Why?
|
| Point-of-Care Systems | 2 | 2011 | 1178 | 0.090 |
Why?
|
| Prospective Studies | 7 | 2024 | 53290 | 0.090 |
Why?
|
| Catheterization, Central Venous | 2 | 2005 | 514 | 0.090 |
Why?
|
| Apoptosis | 2 | 2003 | 9724 | 0.090 |
Why?
|
| Respiration, Artificial | 2 | 2020 | 2569 | 0.090 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2011 | 233 | 0.090 |
Why?
|
| Geriatrics | 1 | 1994 | 397 | 0.090 |
Why?
|
| Public Health | 2 | 2019 | 2602 | 0.090 |
Why?
|
| Attitude to Health | 1 | 2019 | 2052 | 0.090 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2011 | 364 | 0.090 |
Why?
|
| Risk Management | 2 | 2004 | 571 | 0.090 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2011 | 292 | 0.090 |
Why?
|
| Adjuvants, Immunologic | 1 | 1994 | 1000 | 0.080 |
Why?
|
| Utilization Review | 1 | 2011 | 392 | 0.080 |
Why?
|
| HLA-DR Antigens | 2 | 1988 | 645 | 0.080 |
Why?
|
| Guideline Adherence | 2 | 2020 | 2265 | 0.080 |
Why?
|
| Citrates | 2 | 1988 | 131 | 0.080 |
Why?
|
| Recombinant Proteins | 1 | 2019 | 6621 | 0.080 |
Why?
|
| Freezing | 1 | 1989 | 303 | 0.080 |
Why?
|
| Factor V | 1 | 1989 | 178 | 0.080 |
Why?
|
| Antifibrinolytic Agents | 2 | 2010 | 254 | 0.080 |
Why?
|
| Graft vs Host Disease | 4 | 2000 | 2958 | 0.080 |
Why?
|
| HLA-D Antigens | 1 | 1988 | 134 | 0.080 |
Why?
|
| Health Care Rationing | 1 | 1992 | 437 | 0.080 |
Why?
|
| Motivation | 2 | 2010 | 1971 | 0.080 |
Why?
|
| Aortic Valve Insufficiency | 1 | 1992 | 579 | 0.080 |
Why?
|
| Thrombospondins | 1 | 2009 | 198 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 13693 | 0.080 |
Why?
|
| Hematopoietic Stem Cells | 2 | 1999 | 3390 | 0.080 |
Why?
|
| Academic Medical Centers | 3 | 2017 | 2760 | 0.080 |
Why?
|
| Retinal Diseases | 1 | 2014 | 684 | 0.080 |
Why?
|
| Antigens, Surface | 3 | 2002 | 1663 | 0.080 |
Why?
|
| Hepatitis B | 3 | 1991 | 695 | 0.080 |
Why?
|
| Cyclosporins | 1 | 1987 | 220 | 0.080 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 3 | 2020 | 426 | 0.080 |
Why?
|
| Factor XI Deficiency | 1 | 1987 | 18 | 0.080 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1994 | 1837 | 0.080 |
Why?
|
| Optic Nerve | 1 | 2011 | 554 | 0.080 |
Why?
|
| Binding, Competitive | 1 | 2009 | 1157 | 0.070 |
Why?
|
| Mitomycins | 1 | 1987 | 47 | 0.070 |
Why?
|
| Animals | 12 | 2015 | 168768 | 0.070 |
Why?
|
| Administration, Oral | 1 | 2015 | 3914 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 4805 | 0.070 |
Why?
|
| Hospital Records | 2 | 2007 | 95 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2011 | 8642 | 0.070 |
Why?
|
| Health Behavior | 1 | 2019 | 2635 | 0.070 |
Why?
|
| Drug Discovery | 1 | 2015 | 1058 | 0.070 |
Why?
|
| Communicable Diseases | 2 | 2000 | 880 | 0.070 |
Why?
|
| Laboratories | 1 | 2011 | 463 | 0.070 |
Why?
|
| Intensive Care Units | 3 | 2017 | 3680 | 0.070 |
Why?
|
| Antibodies | 3 | 2009 | 2460 | 0.070 |
Why?
|
| Quality Improvement | 2 | 2020 | 3749 | 0.070 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2009 | 401 | 0.070 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 2006 | 103 | 0.070 |
Why?
|
| Ethics, Medical | 1 | 1992 | 792 | 0.070 |
Why?
|
| Patient Advocacy | 2 | 2003 | 353 | 0.070 |
Why?
|
| Bile | 1 | 1987 | 299 | 0.070 |
Why?
|
| Intraoperative Care | 1 | 1990 | 767 | 0.070 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 1987 | 110 | 0.070 |
Why?
|
| Cerebrovascular Circulation | 1 | 2016 | 2732 | 0.070 |
Why?
|
| Erythrocyte Count | 2 | 1997 | 163 | 0.070 |
Why?
|
| Aged | 20 | 2021 | 163288 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2023 | 8949 | 0.070 |
Why?
|
| Canada | 1 | 2011 | 2065 | 0.070 |
Why?
|
| Erythrocyte Aging | 3 | 2002 | 52 | 0.070 |
Why?
|
| Hemin | 2 | 2005 | 50 | 0.070 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2006 | 31 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 3611 | 0.070 |
Why?
|
| Societies, Medical | 2 | 2011 | 3743 | 0.070 |
Why?
|
| Leukocyte Reduction Procedures | 1 | 2005 | 15 | 0.070 |
Why?
|
| Preleukemia | 1 | 1985 | 35 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2015 | 6459 | 0.070 |
Why?
|
| Cluster Analysis | 1 | 2013 | 2715 | 0.070 |
Why?
|
| Cell Adhesion | 1 | 2012 | 3144 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 1799 | 0.070 |
Why?
|
| Hematologic Tests | 1 | 2006 | 240 | 0.070 |
Why?
|
| Hypoglycemia | 1 | 2013 | 861 | 0.070 |
Why?
|
| Health Services | 1 | 2011 | 758 | 0.070 |
Why?
|
| Seizures, Febrile | 1 | 2006 | 111 | 0.060 |
Why?
|
| Anticoagulants | 2 | 1999 | 4600 | 0.060 |
Why?
|
| Heart Valve Diseases | 1 | 2013 | 1074 | 0.060 |
Why?
|
| Ethics, Clinical | 1 | 2006 | 101 | 0.060 |
Why?
|
| Shock | 2 | 2002 | 318 | 0.060 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2005 | 56 | 0.060 |
Why?
|
| History, 19th Century | 1 | 2007 | 720 | 0.060 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 1 | 2005 | 89 | 0.060 |
Why?
|
| Cohort Studies | 6 | 2020 | 40559 | 0.060 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2014 | 1052 | 0.060 |
Why?
|
| Spleen | 1 | 2011 | 2362 | 0.060 |
Why?
|
| Protoporphyria, Erythropoietic | 1 | 2005 | 43 | 0.060 |
Why?
|
| Acute Lung Injury | 1 | 2008 | 380 | 0.060 |
Why?
|
| Drug Evaluation | 1 | 2006 | 647 | 0.060 |
Why?
|
| Logistic Models | 3 | 2018 | 13409 | 0.060 |
Why?
|
| Mitogens | 1 | 1984 | 232 | 0.060 |
Why?
|
| Galactosyltransferases | 1 | 1985 | 264 | 0.060 |
Why?
|
| Sensitivity and Specificity | 4 | 2010 | 14723 | 0.060 |
Why?
|
| Leukocyte Transfusion | 1 | 2003 | 60 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2011 | 17446 | 0.060 |
Why?
|
| Bacteria | 1 | 1995 | 2115 | 0.060 |
Why?
|
| Blood Proteins | 1 | 2009 | 1124 | 0.060 |
Why?
|
| Nigeria | 1 | 2006 | 733 | 0.060 |
Why?
|
| Loa | 1 | 1983 | 5 | 0.060 |
Why?
|
| Blood Volume | 1 | 2005 | 565 | 0.060 |
Why?
|
| Patient Selection | 2 | 2006 | 4216 | 0.060 |
Why?
|
| Receptors, Complement | 1 | 2024 | 264 | 0.060 |
Why?
|
| Pharmacogenetics | 1 | 2007 | 674 | 0.060 |
Why?
|
| Anemia, Megaloblastic | 1 | 1983 | 25 | 0.060 |
Why?
|
| Aortic Valve | 1 | 2013 | 1924 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 1999 | 1677 | 0.060 |
Why?
|
| Publishing | 1 | 2010 | 833 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2007 | 2618 | 0.060 |
Why?
|
| Retina | 1 | 2014 | 2616 | 0.060 |
Why?
|
| Anemia, Macrocytic | 1 | 1983 | 55 | 0.060 |
Why?
|
| Reproducibility of Results | 5 | 2023 | 19905 | 0.050 |
Why?
|
| International Normalized Ratio | 1 | 2004 | 367 | 0.050 |
Why?
|
| Porphyria, Hepatoerythropoietic | 1 | 2002 | 8 | 0.050 |
Why?
|
| Guidelines as Topic | 3 | 2000 | 1405 | 0.050 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2013 | 1537 | 0.050 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3242 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2006 | 780 | 0.050 |
Why?
|
| Blood Group Incompatibility | 1 | 2003 | 146 | 0.050 |
Why?
|
| Survival Rate | 2 | 2017 | 12788 | 0.050 |
Why?
|
| Adenine | 2 | 1984 | 936 | 0.050 |
Why?
|
| Cell Shape | 1 | 2023 | 375 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3135 | 0.050 |
Why?
|
| Bradykinin | 1 | 2002 | 214 | 0.050 |
Why?
|
| Hospital Mortality | 3 | 2010 | 5316 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 6896 | 0.050 |
Why?
|
| Granulocytes | 1 | 1983 | 548 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 5135 | 0.050 |
Why?
|
| Donor Selection | 1 | 2023 | 201 | 0.050 |
Why?
|
| Polyamines | 1 | 2002 | 120 | 0.050 |
Why?
|
| Virus Diseases | 3 | 2002 | 711 | 0.050 |
Why?
|
| History, 21st Century | 1 | 2007 | 1534 | 0.050 |
Why?
|
| Calcium | 2 | 2012 | 5755 | 0.050 |
Why?
|
| Phosphatidylserines | 1 | 2002 | 193 | 0.050 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2006 | 546 | 0.050 |
Why?
|
| Thrombolytic Therapy | 1 | 2010 | 2162 | 0.050 |
Why?
|
| Autoantibodies | 2 | 1986 | 2036 | 0.050 |
Why?
|
| Pregnatrienes | 1 | 2000 | 5 | 0.050 |
Why?
|
| Developing Countries | 1 | 2013 | 2815 | 0.050 |
Why?
|
| Safety Management | 1 | 2006 | 783 | 0.050 |
Why?
|
| Hepatitis B Surface Antigens | 3 | 1991 | 305 | 0.050 |
Why?
|
| Preoperative Care | 2 | 2004 | 2251 | 0.050 |
Why?
|
| Cell Survival | 3 | 2003 | 5882 | 0.050 |
Why?
|
| Travel | 1 | 2006 | 788 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2011 | 3493 | 0.050 |
Why?
|
| Hepatitis C, Chronic | 1 | 2008 | 1031 | 0.050 |
Why?
|
| Skin | 1 | 2014 | 4372 | 0.050 |
Why?
|
| Aortic Valve Stenosis | 1 | 1992 | 1965 | 0.050 |
Why?
|
| Radiation-Protective Agents | 1 | 2000 | 90 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2016 | 8551 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 3773 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 4 | 2000 | 1681 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2006 | 1461 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 1989 | 1783 | 0.040 |
Why?
|
| Binding Sites | 1 | 2009 | 6111 | 0.040 |
Why?
|
| Disinfection | 1 | 2002 | 191 | 0.040 |
Why?
|
| Bronchoscopy | 1 | 2005 | 862 | 0.040 |
Why?
|
| Osmolar Concentration | 1 | 2001 | 683 | 0.040 |
Why?
|
| Gene Products, tax | 1 | 1999 | 51 | 0.040 |
Why?
|
| Rabbits | 1 | 1986 | 4894 | 0.040 |
Why?
|
| Splenectomy | 1 | 2021 | 395 | 0.040 |
Why?
|
| Personnel, Hospital | 1 | 2002 | 283 | 0.040 |
Why?
|
| Fluorometry | 1 | 1999 | 106 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2007 | 2740 | 0.040 |
Why?
|
| Free Radical Scavengers | 1 | 2000 | 216 | 0.040 |
Why?
|
| Hepatitis B virus | 1 | 1982 | 513 | 0.040 |
Why?
|
| Living Donors | 1 | 2023 | 621 | 0.040 |
Why?
|
| Cerebral Hemorrhage | 1 | 2010 | 2647 | 0.040 |
Why?
|
| Carrier State | 1 | 1982 | 518 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2006 | 1504 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 1999 | 403 | 0.040 |
Why?
|
| Education, Medical | 1 | 2010 | 1722 | 0.040 |
Why?
|
| Drug Costs | 1 | 2006 | 1105 | 0.040 |
Why?
|
| Octoxynol | 1 | 1998 | 77 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 1999 | 227 | 0.040 |
Why?
|
| Phenotype | 2 | 2012 | 16367 | 0.040 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 57776 | 0.040 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1983 | 985 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2011 | 8319 | 0.040 |
Why?
|
| Immunoassay | 2 | 1997 | 752 | 0.040 |
Why?
|
| Cytapheresis | 1 | 1997 | 8 | 0.040 |
Why?
|
| Lymphocyte Activation | 2 | 1988 | 5524 | 0.040 |
Why?
|
| Heart | 1 | 2011 | 4464 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 3 | 2004 | 7282 | 0.040 |
Why?
|
| Detergents | 1 | 1998 | 230 | 0.040 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2002 | 1066 | 0.040 |
Why?
|
| Cytokines | 1 | 1992 | 7323 | 0.040 |
Why?
|
| Growth Substances | 1 | 1999 | 784 | 0.040 |
Why?
|
| Models, Animal | 1 | 2003 | 2173 | 0.040 |
Why?
|
| Consensus | 1 | 2006 | 2960 | 0.040 |
Why?
|
| Solvents | 1 | 1998 | 302 | 0.040 |
Why?
|
| Phagocytosis | 1 | 2002 | 1539 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2006 | 1637 | 0.040 |
Why?
|
| Protein Binding | 1 | 2009 | 9384 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2002 | 1183 | 0.030 |
Why?
|
| Fixatives | 1 | 1996 | 94 | 0.030 |
Why?
|
| Duffy Blood-Group System | 1 | 1996 | 58 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2006 | 2926 | 0.030 |
Why?
|
| Genes | 1 | 2000 | 1893 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2002 | 985 | 0.030 |
Why?
|
| Graft Occlusion, Vascular | 1 | 1999 | 549 | 0.030 |
Why?
|
| Intraoperative Period | 2 | 1988 | 520 | 0.030 |
Why?
|
| DNA, Single-Stranded | 1 | 1997 | 355 | 0.030 |
Why?
|
| Workflow | 1 | 2020 | 847 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2008 | 5984 | 0.030 |
Why?
|
| Yersinia enterocolitica | 1 | 1995 | 13 | 0.030 |
Why?
|
| Anemia, Sickle Cell | 1 | 2003 | 1020 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2009 | 15078 | 0.030 |
Why?
|
| Biopsy | 2 | 2004 | 6755 | 0.030 |
Why?
|
| United States Food and Drug Administration | 2 | 2000 | 1584 | 0.030 |
Why?
|
| Microchemistry | 1 | 1994 | 57 | 0.030 |
Why?
|
| Receptors, Interleukin | 1 | 1996 | 245 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2020 | 1184 | 0.030 |
Why?
|
| Antioxidants | 2 | 2000 | 1659 | 0.030 |
Why?
|
| Patient Admission | 1 | 2002 | 1380 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 2002 | 1062 | 0.030 |
Why?
|
| Staphylococcus epidermidis | 1 | 1995 | 117 | 0.030 |
Why?
|
| United States | 6 | 2015 | 69872 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2010 | 9955 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2003 | 6386 | 0.030 |
Why?
|
| Documentation | 1 | 2020 | 871 | 0.030 |
Why?
|
| Focus Groups | 1 | 2019 | 1321 | 0.030 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2015 | 314 | 0.030 |
Why?
|
| Bacterial Infections | 1 | 2002 | 1401 | 0.030 |
Why?
|
| Genome, Human | 1 | 2007 | 4420 | 0.030 |
Why?
|
| Risk Factors | 3 | 2019 | 72296 | 0.030 |
Why?
|
| Base Sequence | 2 | 1997 | 12797 | 0.030 |
Why?
|
| Physician Executives | 1 | 2014 | 128 | 0.030 |
Why?
|
| Interleukin-8 | 2 | 1996 | 690 | 0.030 |
Why?
|
| Adolescent | 5 | 2019 | 85779 | 0.030 |
Why?
|
| Communicable Disease Control | 1 | 2000 | 856 | 0.030 |
Why?
|
| Work | 1 | 2014 | 191 | 0.030 |
Why?
|
| Acute Disease | 2 | 2020 | 7147 | 0.030 |
Why?
|
| Bacterial Adhesion | 1 | 1995 | 316 | 0.030 |
Why?
|
| Chimera | 1 | 1994 | 485 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2018 | 1000 | 0.030 |
Why?
|
| DNA Primers | 1 | 1997 | 2891 | 0.030 |
Why?
|
| Pyrogens | 1 | 1992 | 17 | 0.030 |
Why?
|
| Laboratories, Hospital | 1 | 2014 | 194 | 0.030 |
Why?
|
| Fundus Oculi | 1 | 2014 | 473 | 0.030 |
Why?
|
| International Cooperation | 1 | 1999 | 1420 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2000 | 1547 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 1997 | 1101 | 0.030 |
Why?
|
| Periodicity | 1 | 2014 | 364 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2009 | 2505 | 0.030 |
Why?
|
| Indium Radioisotopes | 1 | 1992 | 118 | 0.030 |
Why?
|
| Electroretinography | 1 | 2014 | 509 | 0.030 |
Why?
|
| Risk Assessment | 3 | 2003 | 23336 | 0.030 |
Why?
|
| Nitrites | 1 | 2012 | 160 | 0.030 |
Why?
|
| Microscopy | 2 | 1996 | 902 | 0.030 |
Why?
|
| Genetic Code | 1 | 1992 | 154 | 0.030 |
Why?
|
| Genetic Techniques | 1 | 1995 | 435 | 0.030 |
Why?
|
| Serum Albumin | 2 | 2012 | 675 | 0.030 |
Why?
|
| Age Factors | 2 | 2019 | 18373 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2006 | 3841 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2019 | 2539 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2021 | 2108 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1993 | 876 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2002 | 5388 | 0.020 |
Why?
|
| Genomics | 1 | 2007 | 5717 | 0.020 |
Why?
|
| Health Policy | 1 | 2004 | 2661 | 0.020 |
Why?
|
| Adenosine Triphosphate | 2 | 2002 | 2027 | 0.020 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 1992 | 293 | 0.020 |
Why?
|
| Calibration | 1 | 1994 | 816 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2002 | 2212 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1992 | 424 | 0.020 |
Why?
|
| Phosphorus | 1 | 2012 | 338 | 0.020 |
Why?
|
| Methods | 1 | 1991 | 1129 | 0.020 |
Why?
|
| Hypoproteinemia | 1 | 1990 | 12 | 0.020 |
Why?
|
| Recurrence | 2 | 2019 | 8340 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2015 | 764 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2003 | 21833 | 0.020 |
Why?
|
| Thoracic Surgery | 1 | 2017 | 719 | 0.020 |
Why?
|
| New York | 1 | 1992 | 886 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2011 | 163 | 0.020 |
Why?
|
| Software | 1 | 2004 | 4441 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 1983 | 2988 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 1999 | 1239 | 0.020 |
Why?
|
| Durable Medical Equipment | 1 | 1989 | 22 | 0.020 |
Why?
|
| Health Personnel | 1 | 2003 | 3219 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1992 | 2556 | 0.020 |
Why?
|
| Fluorescein Angiography | 1 | 2014 | 940 | 0.020 |
Why?
|
| Epitopes | 1 | 1996 | 2571 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 1997 | 1180 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2014 | 1851 | 0.020 |
Why?
|
| Incidence | 2 | 2002 | 20952 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 1987 | 6364 | 0.020 |
Why?
|
| Linear Models | 1 | 1999 | 5953 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 2015 | 1011 | 0.020 |
Why?
|
| Partial Thromboplastin Time | 1 | 1989 | 206 | 0.020 |
Why?
|
| Magnesium | 1 | 2012 | 813 | 0.020 |
Why?
|
| Solubility | 1 | 2010 | 1088 | 0.020 |
Why?
|
| Sterilization | 1 | 1989 | 133 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 3778 | 0.020 |
Why?
|
| Polymers | 1 | 1996 | 1621 | 0.020 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 1988 | 192 | 0.020 |
Why?
|
| Equipment Contamination | 1 | 1989 | 185 | 0.020 |
Why?
|
| Citric Acid | 1 | 1988 | 126 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2007 | 39052 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 1997 | 6366 | 0.020 |
Why?
|
| Alkalosis | 1 | 1987 | 54 | 0.020 |
Why?
|
| Neoplasm Metastasis | 2 | 1990 | 4851 | 0.020 |
Why?
|
| Transferases | 1 | 1987 | 75 | 0.020 |
Why?
|
| Lipid Peroxidation | 2 | 2000 | 270 | 0.020 |
Why?
|
| Macrophages | 1 | 2002 | 5660 | 0.020 |
Why?
|
| Primates | 1 | 1990 | 545 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2000 | 3589 | 0.020 |
Why?
|
| Albumins | 1 | 1990 | 568 | 0.020 |
Why?
|
| RNA Splicing | 1 | 1992 | 908 | 0.020 |
Why?
|
| Self Report | 1 | 2018 | 3553 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 1997 | 5077 | 0.020 |
Why?
|
| Platelet Activation | 1 | 1991 | 674 | 0.020 |
Why?
|
| Melanoma, Experimental | 1 | 1990 | 561 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2012 | 2029 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2009 | 1095 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 1997 | 4328 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 1990 | 2086 | 0.020 |
Why?
|
| Mutation | 1 | 2011 | 29786 | 0.020 |
Why?
|
| Mitomycin | 1 | 1987 | 259 | 0.020 |
Why?
|
| Efficiency, Organizational | 1 | 2011 | 695 | 0.020 |
Why?
|
| Lung | 2 | 2003 | 9857 | 0.020 |
Why?
|
| Neuromuscular Diseases | 1 | 1988 | 247 | 0.020 |
Why?
|
| Antigens, CD | 1 | 1996 | 4026 | 0.020 |
Why?
|
| Cost Savings | 1 | 2011 | 925 | 0.020 |
Why?
|
| Dogs | 1 | 1990 | 3912 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 3020 | 0.020 |
Why?
|
| Physician's Role | 1 | 1992 | 943 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 1994 | 2259 | 0.020 |
Why?
|
| Erythrocyte Membrane | 1 | 1986 | 442 | 0.020 |
Why?
|
| Protoporphyrins | 1 | 2005 | 164 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2017 | 9849 | 0.020 |
Why?
|
| Risk | 2 | 1990 | 9688 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 12244 | 0.020 |
Why?
|
| DNA, Viral | 1 | 1991 | 2227 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 7785 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2002 | 7182 | 0.010 |
Why?
|
| Prognosis | 2 | 2023 | 29060 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2020 | 25628 | 0.010 |
Why?
|
| Probability | 1 | 1989 | 2506 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1983 | 313 | 0.010 |
Why?
|
| Immunization | 1 | 2008 | 1256 | 0.010 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 1990 | 934 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1988 | 2124 | 0.010 |
Why?
|
| Dental Staff | 1 | 1982 | 14 | 0.010 |
Why?
|
| gamma-Globulins | 1 | 1982 | 124 | 0.010 |
Why?
|
| Parvovirus, Porcine | 1 | 2002 | 1 | 0.010 |
Why?
|
| Diarrhea Viruses, Bovine Viral | 1 | 2002 | 6 | 0.010 |
Why?
|
| Medical Staff | 1 | 1982 | 43 | 0.010 |
Why?
|
| Aziridines | 1 | 2002 | 21 | 0.010 |
Why?
|
| Hepatitis B Core Antigens | 1 | 1982 | 92 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 1992 | 3203 | 0.010 |
Why?
|
| Hepatitis B e Antigens | 1 | 1982 | 133 | 0.010 |
Why?
|
| Hepatitis, Viral, Human | 1 | 1982 | 138 | 0.010 |
Why?
|
| Hepatitis B Antibodies | 1 | 1982 | 159 | 0.010 |
Why?
|
| Forecasting | 1 | 1991 | 2951 | 0.010 |
Why?
|
| Mice | 2 | 2003 | 81201 | 0.010 |
Why?
|
| Prevalence | 1 | 2018 | 15221 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 1982 | 418 | 0.010 |
Why?
|
| DNA | 1 | 1995 | 7294 | 0.010 |
Why?
|
| Osmotic Fragility | 1 | 2000 | 37 | 0.010 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 1 | 2000 | 46 | 0.010 |
Why?
|
| Pulmonary Edema | 1 | 2003 | 414 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 2002 | 528 | 0.010 |
Why?
|
| Models, Biological | 1 | 2017 | 9584 | 0.010 |
Why?
|
| Papio | 1 | 2002 | 656 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1992 | 13814 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8385 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 1982 | 592 | 0.010 |
Why?
|
| Massachusetts | 1 | 1992 | 8662 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1984 | 1475 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 1992 | 3531 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 1985 | 1680 | 0.010 |
Why?
|
| Immunologic Memory | 1 | 1986 | 1348 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 1987 | 20824 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 1990 | 2148 | 0.010 |
Why?
|
| Economics, Hospital | 1 | 2000 | 213 | 0.010 |
Why?
|
| Temperature | 1 | 1984 | 2204 | 0.010 |
Why?
|
| Radiation Tolerance | 1 | 2000 | 486 | 0.010 |
Why?
|
| Potassium | 1 | 2002 | 1336 | 0.010 |
Why?
|
| Butylated Hydroxytoluene | 1 | 1997 | 9 | 0.010 |
Why?
|
| Graft Rejection | 2 | 1987 | 4397 | 0.010 |
Why?
|
| Syndrome | 1 | 2003 | 3252 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 25039 | 0.010 |
Why?
|
| Viral Vaccines | 1 | 1982 | 636 | 0.010 |
Why?
|
| Receptors, Interleukin-8A | 1 | 1996 | 44 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1986 | 1887 | 0.010 |
Why?
|
| Haplorhini | 1 | 1996 | 552 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1982 | 1782 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1985 | 2948 | 0.010 |
Why?
|
| Heart Diseases | 1 | 1988 | 2789 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2000 | 2971 | 0.010 |
Why?
|
| Vascular Surgical Procedures | 1 | 2003 | 1476 | 0.010 |
Why?
|
| Kinetics | 1 | 2002 | 6476 | 0.010 |
Why?
|
| Viruses | 1 | 1998 | 375 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2002 | 4777 | 0.010 |
Why?
|
| Critical Illness | 1 | 2006 | 2670 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2011 | 5321 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 1982 | 1862 | 0.010 |
Why?
|
| Decision Making | 1 | 2005 | 3888 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1997 | 2184 | 0.010 |
Why?
|
| Research Design | 1 | 2007 | 5984 | 0.010 |
Why?
|
| Europe | 1 | 1998 | 3338 | 0.010 |
Why?
|
| alpha-2-Antiplasmin | 1 | 1990 | 13 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1984 | 4666 | 0.010 |
Why?
|
| Plasminogen Inactivators | 1 | 1990 | 38 | 0.010 |
Why?
|
| Hemorrhagic Disorders | 1 | 1990 | 36 | 0.010 |
Why?
|
| Plasminogen Activators | 1 | 1990 | 209 | 0.010 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1990 | 188 | 0.010 |
Why?
|
| Observer Variation | 1 | 1996 | 2593 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 1997 | 2076 | 0.010 |
Why?
|
| Cryopreservation | 1 | 1994 | 670 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2000 | 3084 | 0.010 |
Why?
|
| Acid-Base Imbalance | 1 | 1987 | 41 | 0.000 |
Why?
|
| Stroke | 1 | 2010 | 9981 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 1984 | 9274 | 0.000 |
Why?
|
| Computer Simulation | 1 | 2000 | 6194 | 0.000 |
Why?
|
| Aging | 1 | 1986 | 8664 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 1984 | 10183 | 0.000 |
Why?
|
| Blood Gas Analysis | 1 | 1987 | 383 | 0.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1987 | 11525 | 0.000 |
Why?
|
| Lung Diseases, Fungal | 1 | 1986 | 122 | 0.000 |
Why?
|
| Acidosis | 1 | 1987 | 270 | 0.000 |
Why?
|
| Enteral Nutrition | 1 | 1990 | 767 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 35425 | 0.000 |
Why?
|
| Leukemia | 1 | 1990 | 1510 | 0.000 |
Why?
|
| Hemodynamics | 1 | 1992 | 4196 | 0.000 |
Why?
|
| Nutritional Status | 1 | 1990 | 1609 | 0.000 |
Why?
|
| Neoplasms | 1 | 1990 | 21696 | 0.000 |
Why?
|
| Hepatitis C | 1 | 1991 | 1591 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2003 | 20130 | 0.000 |
Why?
|
| Fibrinolytic Agents | 1 | 1990 | 2158 | 0.000 |
Why?
|
| Cytomegalovirus Infections | 1 | 1986 | 820 | 0.000 |
Why?
|